1.- Boban, M. (2021). Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. Int J Clin Pract, 75(4), e13868. doi:10.1111/ijcp.13868 2.- Sigismund, S., Avanzato, D., & Lanzetti, L. (2018). Emerging functions of the EGFR in cancer. Mol Oncol, 12(1), 3-20. doi:10.1002/1878-0261.12155 3.- Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut Med 2020. 4.- Lippi G, Sanchis-Gomar F, Henry BM. COVID-19: unravelling the clinical progression of nature's virtually perfect biological weapon. Ann Transl Med 2020; 8: 693. 5.- Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: understanding nimotuzumab’s clinical effects. Cancers. (2011) 3:2014–31. doi: 10.3390/cancers3022014 6.- Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. (2011) 11:373– 82. doi: 10.4161/cbt.11.4.14097 7.- Rengifo CE, Blanco R, Blanco D, Cedeño M, Frómeta M, Calzado ER Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the Epidermal Growth Factor and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of Patients for Immunotherapy..J Biomark. 2013;2013:627845 8.- Mazorra Z, Lavastida A, Concha-Benavente F, Valdés A, Srivastava RM, García-Bates TM, et al. Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of egfr-specific t cells in head and neck cancer patients. Front Pharmacol. (2017) 8:382